Abstract: A device includes a support (1) and at least two seals (2), which are arranged in a row and are hermetically fitted into cavities, and protrude from the support laterally with respect to inlet and outlet openings, one end of the support being provided with an inlet opening (3) and one end being provided with an outlet opening (4), and the seals being provided with a least one inlet opening and one outlet opening, and the support containing at least one first channel (5) which starts at the inlet opening (3) and is continuous, and is arranged in such a way that it opens into the inlet openings in the side walls of the seals arranged in a row, and one second channel (6) which starts at the outlet opening and is continuous, and is arranged in such a way that it opens into the outlet openings in the side walls of the seals arranged in a row.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: An improved process for the preparation of sertraline hydrochloride polymorphic form II is described, which process comprises seeding a solution of sertraline free amine in a ketone with some crystals of polymorphic form II and addition of hydrogen chloride, and wherein the solution is heated before addition of the hydrogen chloride. According to the present process, the metastable form II may be obtained in a reliable way with good yield and high purity with respect to other polymorphic forms as well as preparative residues such as educts or solvents.

Abstract: The present invention is directed to the polymorphic Form B and the amorphous form of Benazepril hydrochloride. The present invention is also directed to processes for the preparation of Form B and the amorphous form of Benazepril hydrochloride, as well as novel processes for the preparation of Form A. Furthermore, the present invention is directed to pharmaceutical compositions comprising these crystalline forms.

Abstract: A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

Abstract: Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomers of fluvastatin, referred to as polymorphic Forms A, B1, B2, C, D and E, processes for the preparation of these crystalline forms and pharmaceutical compositions comprising them are disclosed.

Abstract: Device consisting of a support (1) and at least two seals (2), which are arranged in a row and are hermetically fitted into cavities, and protrude from the support laterally with respect to inlet and outlet openings, one end of the support being provided with an inlet opening (3) and one end being provided with an outlet opening (4), and the seals being provided with a least one inlet opening and one outlet opening, and the support containing at least one first channel (5) which starts at the inlet opening (3) and is continuous, and is arranged in such a way that it opens into the inlet openings in the side walls of the seals arranged in a row, and one second channel (6) which starts at the outlet opening and is continuous, and is arranged in such a way that it opens into the outlet openings in the side walls of the seals arranged in a row.

Abstract: A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug.

Abstract: Novel crystalline forms of Fluvastatin sodium hydrates were found, referred to hereinafter as polymorphic Forms C, D, E and F. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, a process for the preparation of highly crystalline Fluvastatin sodium Form A, and pharmaceutical compositions comprising the crystalline forms.

Abstract: Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomer of fluvastatin were found, referred to hereinafter as polymorphic Forms A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: Novel crystalline forms of Fluvastatin sodium hydrates were found, referred to hereinafter as polymorphic Forms C, D, E and F. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, a process for the preparation of highly crystalline Fluvastatin sodium Form A, and pharmaceutical compositions comprising the crystalline forms.